Brief: Nabriva Therapeutics Appoints Daniel Dolan As Chief Financial Officer
26/02/2021 14:47
Feb 26 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS APPOINTS DANIEL DOLAN AS CHIEF
FINANCIAL
OFFICER
* NABRIVA THERAPEUTICS - APPOINTMENT OF DANIEL DOLAN AS CFO
EFFECTIVE CLOSE OF BUSINESS MARCH 12
* NABRIVA THERAPEUTICS PLC - DOLAN WILL REPLACE CURRENT CFO
GARY
SENDER, WHO IS RETIRING FROM CO
* NABRIVA THERAPEUTICS PLC - SENDER WILL SERVE AS A
CONSULTANT FOR
NABRIVA AT LEAST THROUGH REMAINDER OF 2021
Source text for Eikon: ID:nGNXq50Zv
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update